跳至主要内容
临床试验/NCT07065539
NCT07065539尚未招募不适用

The Impact of Duration of Gonadotropin-Releasing Hormone Agonist Pretreatment and Letrozole Supplementation on Pregnancy Outcomes in Frozen-Thawed Embryo Transfer Cycles for Patients With Adenomyosis: A 2 by 2 Factorial Multicenter, Randomized Controlled Trial

First Affiliated Hospital, Sun Yat-Sen University1 个研究点 分布在 1 个国家目标入组 432 人开始时间: 2025年7月20日最近更新:
干预措施
相关药物

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
432
试验地点
1
主要终点
Live birth rate

研究概览

简要总结

This randomized clinical trial aims to assess the comparative effectiveness of different pre-treatment protocols prior to frozen embryo transfer (FET) among women with adenomyosis, providing evidence-based guidance for clinical decision-making. The main questions it aims to answer are:

Does the protocol involving two doses of gonadotropin-releasing hormone agonist (GnRH-a) pretreatment result in a higher live birth rate compared to one dose of GnRH-a pretreatment in women with adenomyosis undergoing frozen embryo transfer? Does the protocol involving GnRH-a with letrozole supplementation result in a higher live birth rate compared to GnRH-a monotherapy in women with adenomyosis undergoing frozen embryo transfer? Eligible participants will undergo screening before endometrial preparation for FET, following which they will be randomly assigned to one of four groups: GnRH-a-1M, GnRH-a-2M, GnRH-a+LE-1M or GnRH-a+LE-2M. In the GnRH-a-1M group, participants will be pre-treated with one dose GnRH agonist before endometrial preparation. In the GnRH-a-2M group, participants will be pre-treated with two doses GnRH agonist before endometrial preparation. In the GnRH-a+LE-1M group, participants will be pre-treated with one dose GnRH agonist and letrozole 28 days before endometrial preparation. In the GnRH-a+LE-2M group, participants will be pre-treated with two doses GnRH agonist, along with daily 2.5 mg letrozole for 28 days since the first injection of GnRH agonist before endometrial preparation. After pre-treament, all participants will return for endometrial preparation in artificial cycles.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 38 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Sonographically diagnosed adenomyosis via transvaginal ultrasound;
  • Candidates scheduled for frozen single blastocyst (Day5, Day6) transfer
  • Age 20-38 years
  • Previous embryo transfer attempts: ≤2 cycles

排除标准

  • Patients diagnosed with Recurrent pregnancy loss, Autoimmune disorders (e.g., systemic lupus erythematosus), Uterine fibroids ≥5 cm, Cervical incompetence, Cesarean scar niche
  • History of Myomectomy and/or adenomyosis lesion excision, Cervical conization
  • Patients presenting with Congenital Müllerian anomalies (unicornuate uterus, septate uterus, etc.), Endometrial atypical hyperplasia, malignancy or defects
  • Sperm retrieval method: Micro-TESE (microdissection testicular sperm extraction)
  • Fertilization method: Rescue ICSI
  • Endometrial thickness <7 mm, Intrauterine adhesions, Intrauterine fluid
  • Contraindications to exogenous hormone administration
  • Use of GnRH within 3 months prior to enrollment

研究组 & 干预措施

GnRH-a-1M

Active Comparator

干预措施: GnRH-a-1M (Drug)

GnRH-a-2M

Active Comparator

干预措施: GnRH-a-2M (Drug)

GnRH-a+LE-1M

Active Comparator

干预措施: GnRH-a+LE-1M (Drug)

GnRH-a+LE-2M

Active Comparator

干预措施: GnRH-a+LE-2M (Drug)

结局指标

主要结局

Live birth rate

时间窗: 40 weeks after embryo transfer

次要结局

  • Cycle Cancellation Rate(3 weeks after initiating artificial cycle)
  • Hypoestrogenic Adverse Event Rate(4 weeks after 3.75mg GnRH-a intramuscular injection)
  • Embryo Implantation Rate(3 weeks post embryo transfer)
  • Positive Pregnancy Test Rate(2 weeks post embryo transfer)
  • Clinical Pregnancy Rate(5 weeks post embryo transfer)
  • Ectopic Pregnancy Rate(7 weeks' gestation)
  • Ongoing Pregnancy Rate(10 weeks post embryo transfer)
  • Miscarriage Rate(Prior to 28 weeks' gestation)
  • Drug-Related Venous Thromboembolism (VTE) Rate(Treatment initiation until 10 weeks' gestation)
  • Preterm Birth Rate(22, 28, 32, 37 weeks' gestation)
  • Gestational Diabetes Mellitus (GDM) Incidence(24-28 weeks' gestation)
  • Rate of Hypertension in Pregnancy(20 weeks' gestation to delivery)
  • Low Birth Weight Rate(Delivery)
  • Very Low Birth Weight Rate(Delivery)
  • Macrosomia Rate(Delivery)
  • Extreme Macrosomia Rate(Delivery)
  • Multiple Pregnancy Rate(6-8 weeks' gestation)
  • Stillbirth Rate(28 weeks' gestation to delivery)
  • Neonatal Mortality Rate(First 28 days postnatal)
  • Adverse Event Incidence(Enrollment until 6 months postpartum)

研究者

发起方
First Affiliated Hospital, Sun Yat-Sen University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yanwen Xu

Director of the Reproductive Medical Center, the First Affliated Hospital of Sun Yat-sen University

First Affiliated Hospital, Sun Yat-Sen University

研究点 (1)

Loading locations...

相似试验